Avexima celebrates Its 14th anniversar

The pharmaceutical company Avexima celebrates its 14th anniversary. Over these years, it has evolved from a newcomer to the pharmaceutical market into one of the key Russian manufacturers, having established a powerful production complex, a modern research center, and united a team of highly qualified specialists.

Today, the company's portfolio includes over 120 drugs for the treatment of various diseases. Many of them are included in the list of Vital and Essential Drugs (VED) and are supplied not only to Russian regions but also abroad.

«Our priorities are strengthening our market position and contributing to the country's pharmaceutical independence. We intend to enhance the efficiency of drug supply within the framework of 'Pharma-2030,' focusing on continuous modernization, advanced technologies, and team qualification development», noted Ivan Khalepo, General Director of JSC Avexima.

The company's achievements and the recognition of its products are evidenced by authoritative awards and expert assessments:

• According to analysts at CURSOR, Avexima is one of Russia's leading pharmaceutical companies;

• Drugs of the NOBAZIT® brand are included in the clinical guidelines of the Russian Ministry of Health for treating viral pneumonia, ARVI, and influenza in adults, in the Standard of Medical Care for Adults with ARVI, in the 19th version of the interim methodological recommendations for the prevention, diagnosis, and treatment of coronavirus infection, as well as in the methodological recommendations of the Russian National Medical Association of Therapists (RNMAT) for the diagnosis, prevention, treatment, and rehabilitation of viral lung damage in SARS-CoV-2 infection;

• Drugs METROMICON-NEO® and PRIMAFUNGIN® are included in the clinical guidelines of the Russian Ministry of Health for treating bacterial vaginosis and candidal vulvovaginitis;

•  Avexima and the drug Devilam are in the top 10 of the «AlphaRM» rating for pharmacy sales of vitamin D;

• The drug Devilam won 3rd place in the prestigious «Platinum Uncia» competition;

• The drug TARGIFORT® became a bronze prize-winner in one of the nominations of the Russian Pharma Awards®;

• According to a study by RNC Pharma, the company is the leader in furacilin production in Russia.

The company's status as a finalist in the international «GxP-Profi 2025» competition serves as additional confirmation of the high standards of Avexima's operations.

These represent only a portion of the company's significant successes and key achievements of the company over its 14 years of operation in the Russian pharmaceutical market.

The Avexima team sees its mission as producing in-demand, high-quality medicines every day, helping millions of people maintain their health and live life to the fullest.